Proficio Capital Partners LLC Purchases Shares of 46,089 MiMedx Group, Inc. (NASDAQ:MDXG)

Proficio Capital Partners LLC bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 46,089 shares of the company's stock, valued at approximately $443,000.

Several other large investors also recently added to or reduced their stakes in MDXG. Van ECK Associates Corp bought a new stake in shares of MiMedx Group during the 4th quarter valued at $40,000. Point72 DIFC Ltd lifted its position in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after acquiring an additional 4,275 shares in the last quarter. Savant Capital LLC purchased a new stake in shares of MiMedx Group during the fourth quarter worth about $100,000. Orion Capital Management LLC raised its stake in MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company's stock valued at $69,000 after purchasing an additional 3,700 shares during the period. Finally, SkyView Investment Advisors LLC grew its holdings in MiMedx Group by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock valued at $77,000 after buying an additional 3,000 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Trading Down 2.6 %

MDXG stock traded down $0.20 during mid-day trading on Friday, reaching $7.54. 472,215 shares of the stock traded hands, compared to its average volume of 705,885. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The stock has a market capitalization of $1.11 billion, a PE ratio of 13.71 and a beta of 1.97. The business has a 50-day moving average price of $8.30 and a two-hundred day moving average price of $7.89.

Remove Ads

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th.

Insider Transactions at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares in the company, valued at $3,473,004.42. The trade was a 11.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. Insiders own 1.30% of the company's stock.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.